poisons-list-alpha.pdf

8/10/2019 poisons-list-alpha.pdf

1/100

TG147/97 Page 1of 100

MINISTRY OF HEALTH, NEW SOUTH WALES

POISONS LIST2013

ALPHABETICAL LIST OF POISONS, RESTRICTED SUBSTANCES AND DRUGS OF ADDICTION

(Includes amendments up to and including 1 September 2013)

The following alphabetical list has been prepared for the guidance of users but has no legal status. For exactreference, use should be made of the entries in the Poisons List itself.

This list, exceptfor a very small number of variations, is based on the Standard for the Uniform Scheduling ofMedicines and Poisons No. 4 (S.U.S.M.P. No. 4) and Amendment No. 1 to S.U.S.M.P. No.4.

It should be noted that the entries are for substances. In the Poisons and Therapeutic Goods Act, 1966,"substance" is defined to include preparation, admixture and all salts and derivatives. However, scheduledsubstances when contained in certain products are exempt and these exemptions are listed at the end of eachSchedule, and these products are generally those shown in Appendix A to the S.U.S.M.P.

Certain entries in this List appear with a "Clause" or "Appendix" number in parentheses. These referrespectively to the Clauses of the Poisons and Therapeutic Goods Regulation 2008 under the Poisons andTherapeutic Goods Act 1966 which make special or additional reference to the substance concerned or tolisting in the appropriate Appendix of the Poisons and Therapeutic Goods Regulation 2008.

In the Index, number and single-letter prefixes are ignored for alphabetical listing._______________________________________________________________________________________

SCHEDULE SUBSTANCE

_______________________________________________________________________________________4 ABACAVIR.7 ABAMECTIN exceptwhen included in Schedule 5 or 6.

6 ABAMECTIN:(a) in preparations for pesticidal use containing 4 per cent or less of abamectin except when

included in Schedule 5; or(b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of

abamectin.5 ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent

or less of abamectin.4 ABATACEPT.

4 ABCIXIMAB.4 ABIRATERONE ACETATE7 ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.5 ABSCISIC ACID.4 ACAMPROSATE CALCIUM.4 ACARBOSE.4 ACEBUTOLOL.6 ACEPHATE.4 ACEPROMAZINE.6 ACETAMIPRID exceptin preparations containing 1 per cent or less of acetamiprid.4 ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human

therapeutic use.

4 ACETARSOL.4 ACETAZOLAMIDE.6 ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per

cent acetic acid (CH3COOH) exceptwhen included in Schedule 2.


2/100

TG147/97 Page 2of 100

2 ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 percent of acetic acid (CH3

5 ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 percent of acetic acid (CH

COOH) for therapeutic use.

3

(a) when included in Schedule 2 or 6; orCOOH) except:

(b) for therapeutic use.6 ACETIC ANHYDRIDE excluding its derivatives.4 ACETOHEXAMIDE.

5 ACETONE exceptin preparations containing 25 per cent or less of designated solvents.4 ACETYL ISOVALERYLTYLOSIN.4 ACETYLCARBROMAL.4 ACETYLCHOLINE.4 ACETYLCYSTEINE except:

(a) when included in Schedule 2; or(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less

of acetylcysteine.2 ACETYLCYSTEINE in preparations for oral use exceptwhen labelled with a recommended daily

dose of 1 g or less of acetylcysteine.4 ACETYLDIGITOXIN.8 ACETYLDIHYDROCODEINE.

8 ACETYLMETHADOL.4 ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.8 ACETYLMORPHINES.4 ACETYLSTROPHANTHIDIN.7 ACIBENZOLAR-S-METHYL.4 ACICLOVIR exceptin preparations containing 5 per cent or less of aciclovir for the treatment of

Herpes labialis in packs containing 10 g or less.6 ACIFLUORFEN.6 ACINITRAZOLE exceptin preparations containing 20 per cent or less of acinitrazole.

4 ACIPIMOX.4 ACITRETIN. (Clauses 37,52,60)4 ACLIDINIUM BROMIDE.

4 ACOKANTHERA OUABAIO.4 ACOKANTHERA SCHIMPERI.4 ACONITUM spp except:

(a) when included in Schedule 2;(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids;

or(c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids

in packs containing 0.02 mg or less of total alkaloids.2 ACONITUM spp for therapeutic use in adults:

(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloidsexceptin packs containing 0.02 mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packseach containing 0.2 mg or less of total alkaloids exceptin packs containing 0.02 mg orless of total alkaloids.

7 ACORUS CALAMUS (calamus) for human therapeutic use.7 ACRIFLAVINE for veterinary use exceptwhen included in Schedule 5.5 ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.4 ACRIVASTINE.7 ACROLEIN.7 ACRYLONITRILE.4 ADALIMUMAB.4 ADAPALENE.4 ADEFOVIR.

4 ADENOSINE for human therapeutic use in preparations for injection.4 ADIPHENINE.4 ADONIS VERNALIS.4 ADRAFINIL.4 ADRENALINE except:


3/100

TG147/97 Page 3of 100

(a) when included in Schedule 3; or(b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelledfor injection.

3 ADRENALINE in preparations containing 1 per cent or less of adrenaline exceptin preparationscontaining 0.02 per cent or less of adrenalineunless packed and labelled for injection.

4 ADRENOCORTICAL HORMONES exceptwhen separately specified in these Schedules.

4 AFAMELANOTIDE (Melanocyte stimulating hormone).AFLIBERCEPT.

4 AGALSIDASE.4 AGLEPRISTONE.4 AGOMELATINE.5 AKLOMIDE.7 ALACHLOR.4 ALATROFLOXACIN MESYLATE.4 ALBENDAZOLE except:

(a) when included in Schedule 5 or 6; or(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of

animals.6 ALBENDAZOLE for the treatment of animals except:

(a) when included in Schedule 5; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole.5 ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of

albendazole exceptin intraruminal implants each containing 3.85 g or less of albendazole.4 ALCLOFENAC.4 ALCLOMETASONE exceptwhen included in Schedule 3.3 ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use

containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of thepreparation.ALCOHOL - see METHYLATED SPIRIT.ALCOHOL ANTAGONISTS - see individual entries.

4 ALCURONIUM.4 ALDESLEUKIN.

7 ALDICARB.4 ALDOSTERONE.7 ALDOXYCARB.6 ALDRIN.4 ALEFACEPT.4 ALEMTUZUMAB.4 ALENDRONIC ACID.4 ALFACALCIDOL.8 ALFENTANIL.4 ALFUZOSIN.

Exempt ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition ofan agvet chemical product.

4 ALGLUCERASE.4 ALGLUCOSIDASE.4 ALISKIREN.5 ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium

alone or in any combination:(a) in solid orthodontic device cleaning preparations, the pH of which as an in-use aqueous

solution is more than 11.5;(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous

solutions or mixture is more than 11.5 but less than or equal to 12.5;(c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than

11.5; or

(d) in liquid or semi-solid preparations the pH of which is more than 11.5, unless:(i) in food additive preparations for domestic use; or(ii) in automatic dish washing preparations for domestic use with a pH of more than

12.5,exceptwhen separately specified in these Schedules.


4/100

TG147/97 Page 4of 100

6 ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassiumalone or in any combination for non-domestic use:(a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous

solution or mixture is more than 12.5; or(b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than

12.5.7 ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium,

alone or in any combination for domestic use:

(a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueoussolutions or mixture is more than 12.5; or

(c) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than12.5.

6 ALKOXYLATED FATTY ALKYLAMINE POLYMER except:(a) when included in Schedule 5; or(b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

5 ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or lessof alkoxylated fatty alkylamine polymer exceptin preparations containing 20 per cent or less ofalkoxylated fatty alkylamine polymer.

4 ALLERGENS.

6 ALLETHRIN except:(a) when included in Schedule 5; or(b) in insecticidal mats containing 20 per cent or less of allethrin; or(c) in other preparations containing 1 per cent or less of allethrin.

5 ALLETHRIN in preparations containing 10 per cent or less of allethrin except:

(a) in insecticidal mats; or(b) in other preparations containing 1 per cent or less of allethrin.

4 ALLOPURINOL.5 ALLOXYDIM.7 ALLYL ALCOHOL.7 ALLYLISOPROPYLACETYLUREA for therapeutic use.4 ALLYLOESTRENOL.

4 ALOGLIPTIN4 ALOSETRON.2 ALOXIPRIN.8 ALPHACETYLMETHADOL.7 ALPHA-CYPERMETHRIN exceptwhen included in Schedule 5 or 6.

6 ALPHA-CYPERMETHRIN(a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or(b) in other preparations containing 10 per cent or less of alpha-cypermethrin,exceptwhen included in Schedule 5.

5 ALPHA-CYPERMETHRIN:(a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or(b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

4 ALPHADOLONE.8 ALPHAPRODINE.4 ALPHA1-PROTEINASE INHIBITOR (HUMAN).4 ALPHAXALONE.4 ALPRAZOLAM. (Appendix A, Appendix D)4 ALPRENOLOL.4 ALPROSTADIL.4 ALSEROXYLON.4 ALTEPLASE.4 ALTRENOGEST.4 ALTRETAMINE (hexamethylmelamine).

4 AMANTADINE.4 AMBENONIUM CHLORIDE.4 AMBRISENTAN.4 AMBUCETAMIDE.4 AMBUTONIUM BROMIDE.


5/100

TG147/97 Page 5of 100

4 AMCINONIDE.4 AMETHOCAINE except:

(a) when included in Schedule 2; or(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

2 AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent orless of total local anaesthetic substances, exceptin dermal preparations containing 2 per cent or

less of total local anaesthetic substances.5 AMETRYN.

6 AMICARBAZONE.6 AMIDITHION.4 AMIFOSTINE.4 AMIKACIN.4 AMILORIDE.7 AMINACRINE for veterinary use exceptwhen included in Schedule 5.5 AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.5 AMINES for use as curing agents for epoxy resins exceptwhen separately specified in these

Schedules.4 AMINOCAPROIC ACID.7 AMINOCARB exceptwhen included in Schedule 6.6 AMINOCARB in preparations containing 25 per cent or less of aminocarb.

5 AMINOCYCLOPYRACHLOR.6 AMINOETHOXYVINYLGLYCINE exceptin preparations containing 15 per cent or less of

aminoethoxyvinylglycine.4 AMINOGLUTETHIMIDE.4 5-AMINOLEVULINIC ACID6 1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.4 AMINOMETRADINE.7 AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.4 AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.4 AMINOPHYLLINE exceptwhen included in Schedule 3.3 AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.4 AMINOPTERIN.

6 AMINOPYRALID.7 4-AMINOPYRIDINE exceptwhen included in Schedule 4.4 4-AMINOPYRIDINE for therapeutic use.4 AMINOREX.4 AMINOSALICYLIC ACID.4 AMIODARONE.4 AMIPHENAZOLE.4 AMISOMETRADINE.4 AMISULPRIDE. (Appendix A)7 AMITON.6 AMITRAZ.4 AMITRIPTYLINE. (Appendix A)5 AMITROLE.4 AMLODIPINE.4 AMMI VISNAGA.6 AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:

(a) when included in Schedule 5;(b) in preparations for human internal therapeutic use;(c) in preparations for inhalation when absorbed in an inert solid material; or(d) in preparations containing 0.5 per cent or less of ammonia.

5 AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparationscontaining 5 per cent or less of ammonia except:(a) in preparations for human internal therapeutic use;

(b) in preparations for inhalation when absorbed in an inert solid material; or(c) in preparations containing 0.5 per cent or less of free ammonia.4 AMMONIUM BROMIDE for therapeutic use.6 AMMONIUM PERSULFATE in hair preparations.5 AMMONIUM THIOCYANATE exceptin preparations containing 10 per cent or less of


6/100

TG147/97 Page 6of 100

ammonium thiocyanate.4 AMODIAQUINE.4 AMOROLFINE except:

(a) when included in Schedule 2; or(b) in preparations for the treatment of tinea pedis.

2 AMOROLFINE in preparations for topical use exceptin preparations for the treatment of tinea

pedis.4 AMOXAPINE.

4 AMOXYCILLIN.8 AMPHETAMINE. (Clauses 84,90,98,101,122, Appendix A)4 AMPHOMYCIN.4 AMPHOTERICIN.4 AMPICILLIN.4 AMPRENAVIR.4 AMRINONE.4 AMSACRINE.7 AMYGDALIN for therapeutic use.4 AMYL NITRITE.8 AMYLOBARBITONE exceptwhen included in Schedule 4. (Appendix A)4 AMYLOBARBITONE when packed and labelled for injection. (Appendix A, Appendix B, Appendix

D)4 AMYLOCAINE.4 ANABOLIC STEROIDAL AGENTS. (Appendix B, Appendix D)

ANAESTHETICS - LOCAL - see individual entries.4 ANAGRELIDE.4 ANAKINRA.

ANALEPTICS - see individual entries.4 ANASTROZOLE.4 ANCESTIM.7 ANCHUSA OFFICINALIS for therapeutic use.4 ANCROD and its immunoglobulin antidote.4 ANDROGENIC STEROIDAL AGENTS. (Appendix B, Appendix D)

4 ANDROISOXAZOLE. (Appendix B, Appendix D)4 ANDROSTANOLONE. (Appendix B, Appendix D)4 ANDROSTENEDIOL. (Appendix B, Appendix D)4 ANDROSTENEDIONE. (Appendix B, Appendix D)4 ANECORTAVE.4 ANGIOTENSIN AMIDE.5 ANHYDRIDES, ORGANIC ACID, for use as curing agents for epoxy resins exceptwhen

separately specified in these Schedules.4 ANIDULAFUNGIN.6 ANILINE (excluding its salts and derivatives) exceptin preparations containing 1 per cent or less

of aniline.8 ANILERIDINE.5 ANISE OIL except:

(a) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 50 mL or less fitted with a restricted flow insert and compliant with therequirements of the Required Advisory Statements for Medicine Labels;

(b) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity of 50 mL or less fitted with a restricted flow insert,and labelled with the warning:KEEP OUT OF THE REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of anise oil.4 ANISTREPLASE.4 ANTAZOLINE exceptwhen included in Schedule 2.

2 ANTAZOLINE in eye drops.4 ANTIBIOTIC SUBSTANCES except:(a) when separately specified in these Schedules; or(b) nisin.ANTICHOLINERGICS - see individual entries.


7/100

TG147/97 Page 7of 100

ANTICHOLINESTERASES - see individual entries.ANTICOAGULANTS - see individual entries.ANTICONVULSANTS - see individual entries.ANTIDIABETICS - see individual entries.

4 ANTIGENS for human therapeutic use exceptwhen separately specified in this Schedule.4 ANTIHISTAMINES except:

(a) when included in Schedule 2 or 3; or(b) when separately specified in this Schedule.

ANTILEPROTICS - see individual entries.ANTIMALARIALS - see individual entries.4 ANTIMONY for therapeutic use exceptwhen separately specified in these Schedules.6 ANTIMONY COMPOUNDS except:

(a) when included in Schedule 4;(b) antimony chloride in polishes;(c) antimony titanate pigments in paint; or(d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile

content of the paint or tinter.ANTIPARKINSONIANS - see individual entries.

4 ANTISERA (immunosera) for human use by injection exceptwhen separately specified in theseSchedules.

ANTITHYROIDS - see individual entries.ANTITUBERCULARS - see individual entries.

4 APIXABAN.4 APOCYNUM spp.4 APOMORPHINE.4 APRACLONIDINE.4 APRAMYCIN.4 APREPITANT.4 APRONAL.4 APROTININ.4 ARECOLINE.4 ARIPIPRAZOLE. (Appendix A)

7 ARISTOLOCHIA spp. for therapeutic use.7 ARISTOLOCHIC ACID(S) for human therapeutic use.

AROMATIC EXTRACT OILS see HYDROCARBONS LIQUID AROMATIC.7 ARPRINOCID.7 ARSENIC except:

(a) when separately specified in this Schedule;(b) when included in Schedule 4 or 6;(c) as selenium arsenide in photocopier drums;(d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of

arsenic;(e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded

and moulded articles containing 160 mg/kg or less of arsenic other than when included inarticles:(i) in contact with food stuffs, animal feeds or potable water;(ii) of clothing and footwear in contact with the skin;(iii) used as infant wear; or(iv) intended for use as packaging materials;

(f) in animal feeds containing 75 g/tonne or less of arsenic; or(g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content

of the paint. (Clause 20)6 ARSENIC:

(a) in ant poisons containing 0.4 per cent or less of arsenic;(b) in animal feed premixes containing 4 per cent or less of arsenic; or

(c) in preparations for the treatment of animals exceptthiacetarsamide when included inSchedule 4,exceptwhen separately specified in this Schedule.

4 ARSENIC for human therapeutic use exceptwhen separately specified in these Schedules.4 ARTEMETHER.


8/100

TG147/97 Page 8of 100

4 ARTICAINE.7 ASARUM spp. containing aristolochic acid(s) for human therapeutic use.4 ASENAPINE. (Appendix A)2 ASPIRIN except:

(a) when included in Schedule 4, 5 or 6;(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of

aspirin as the only therapeutically active constituent other than an effervescent agentwhen:

(i) enclosed in a primary pack that contains 12 or less such powders or sachets ofgranules; and(ii) compliant with the requirements of the Required Advisory Statements for

Medicine Labels;(c) in tablets or capsules each containing no other therapeutically active constituent other

than an effervescent agent when:(i) packed in blister or strip packaging or in a container with a child-resistant closure;(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg

or less of aspirin, or in a primary pack of not more than 16 tablets or capsules,each containing 500 mg or less of aspirin; and

(iii) compliant with the requirements of the Required Advisory Statements forMedicine Labels;

(d) in tablets or capsules each containing no other therapeutically active constituent otherthan an effervescent agent when:(i) packed in blister or strip packaging or in a container with a child-resistant closure;(ii) in a primary pack containing 100 or less tablets or capsules, each containing 100

mg or less of aspirin when packed and labelled for the prevention ofcardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the Required Advisory Statements forMedicine Labels.

6 ASPIRIN for the treatment of animals exceptwhen included in Schedule 4 or 5.5 ASPIRIN for the treatment of animals in divided preparations when packed in blister or strip

packaging or in a container with a child-resistant closure.4 ASPIRIN:

(a) when combined with caffeine, paracetamol or salicylamide or any derivative of thesesubstances; or

(b) for injection.4 ASTEMIZOLE.4 ATAMESTANE. (Appendix B, Appendix D)4 ATAZANAVIR.4 ATENOLOL.4 ATIPAMEZOLE.4 ATOMOXETINE.4 ATORVASTATIN.4 ATOSIBAN.4 ATOVAQUONE.4 ATRACURIUM BESYLATE.5 ATRAZINE.4 ATROPA BELLADONNA (belladonna) exceptwhen included in Schedule 2.

2 ATROPA BELLADONNA (belladonna):(a) for external use in preparations containing 0.03 per cent or less of total solanaceous

alkaloids; or(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceousalkaloids when labelled with a dose of 0.3 mg or less of total solanaceousalkaloids and a recommended daily dose of 1.2 mg or less of total solanaceousalkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloidsper dosage unit, when labelled with a recommended daily dose of 1.2 mg or lessof total solanaceous alkaloids.

4 ATROPINE exceptwhen included in Schedule 2.2 ATROPINE (excluding atropine methonitrate) for oral use:


9/100

TG147/97 Page 9of 100

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloidswhen labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and arecommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids perdosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceousalkaloids.

4 ATROPINE METHONITRATE.4 AURANOFIN.

4 AUROTHIOMALATE SODIUM.4 AVILAMYCIN, except:(a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

4 AVIPTADIL.4 AVOPARCIN.4 AXITINIB4 AZACITIDINE.6 AZACONAZOLE exceptin preparations containing 1 per cent or less of azaconazole.4 AZACYCLONOL.7 AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human

internal use exceptdebitterised neem seed oil.

6 AZADIRACHTA INDICA (neem) including its extracts and derivatives except:(a) when included in Schedule 5;(b) in preparations for human internal use;(c) debitterised neem seed oil;(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil,

when in a container fitted with a child-resistant closure and compliant with therequirements of the Requited Advisory Statements for Medicine Labels; or

(e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seedoil.

5 AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels usingwater, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, foragricultural use.

7 AZAFENIDIN.6 AZAMETHIPHOS.4 AZAPERONE.4 AZAPROPAZONE.4 AZARIBINE.4 AZATADINE exceptwhen included in Schedule 3. (Appendix A)3 AZATADINE in oral preparations. (Appendix A)4 AZATHIOPRINE.4 AZELAIC ACID except:

(a) when included in Schedule 2; or(b) in preparations containing 1 percent or less of azelaic acid for non-human use.

2 AZELAIC ACID in dermal preparations.4 AZELASTINE exceptwhen included in Schedule 2.2 AZELASTINE

(a) in preparations for nasal use; or(b) in topical eye preparations containing 0.05 per cent or less of

azelastine.7 AZINPHOS-ETHYL.7 AZINPHOS-METHYL.4 AZITHROMYCIN.4 AZLOCILLIN.6 AZOBENZENE.7 AZOCYCLOTIN.

5 AZOXYSTROBIN.4 AZTREONAM.4 BACAMPICILLIN.5 BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas

fluorescens.


10/100

TG147/97 Page 10of 100

4 BACITRACIN.4 BACLOFEN. (Appendix A)

Exempt BACTERIAL CULTURE MEDIA containing antibiotics.4 BALSALAZIDE.4 BAMBERMYCIN (flavophospholipol) except:

(a) when included in Schedule 6; or(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

6 BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2

per cent or less of antibiotic substances.4 BAMBUTEROL.4 BAMETHAN.4 BAMIPINE.4 BARBITURATES exceptwhen separately specified in these Schedules. (Appendix A, Appendix

D)6 BARIUM SALTS except:

(a) when included in Schedule 5;(b) barium sulfate; or(c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile

content of the paint or tinter.5 BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium

silicofluoride per sq. cm.6 BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except:

(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or(b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the

immediate container and primary pack are labelled with the following statements:KEEP OUT OF REACH OF CHILDREN;If in eyes wash out immediately with water; andWARNING This product contains ingredients which may cause skin irritation to certainindividuals. A preliminary test according to the accompanying directions should be madebefore use. This product must not be used for dyeing eyelashes or eyebrows; to do somay be injurious to the eye.

written in letters not less than 1.5 mm in height.

7 BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) inpreparations for skin colouration and dyeing of eyelashes or eyebrows.

5 BASIL OIL except:(a) in medicines for human therapeutic use, when packed in containers having a nominal

capacity of 25 mL or less fitted with a restricted flow insert and compliant with therequirements of the Required Advisory Statements for Medicine Labels;

(b) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity of 25 mL or less fitted with a restricted flow insert,and labelled with the warning:KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5 per cent or less of methyl chavicol.4 BASILIXIMAB.6 BAY OIL except:

(a) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 15 mL or less fitted with a restricted flow insert and compliant with therequirements of the Requited Advisory Statements for Medicine Labels;

(b) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 25 mL or less fitted with a restricted flow insert and child-resistant closure andcompliant with the requirements of the Required Advisory Statements for MedicineLabels;

(c) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity of 15 mL or less fitted with a restricted flow insertand labelled with the warnings:

KEEP OUT OF THE REACH OF CHILDREN; andNOT TO BE TAKEN;(d) in preparations other than medicines for human therapeutic use, when packed in

containers having a nominal capacity of 25 mL or less fitted with a restricted flow insertand labelled with the warnings:


11/100

TG147/97 Page 11of 100

KEEP OUT OF THE REACH OF CHILDREN; andNOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of bay oil.4 BAZEDOXIFENE.6 BEAUVERIA BASSIANA exceptwhen included in Schedule 5.5 BEAUVERIA BASSIANA in preparations containing 1 x 108

4 BECAPLERMIN.

Colony Forming Units (CFU)/mL orless of Beauvaria bassiana.

4 BECLAMIDE.4 BECLOMETHASONE exceptwhen included in Schedule 2.2 BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of

beclomethasone per actuation when the maximum recommended daily dose is no greater than400 micrograms and when packed in a primary pack containing 200 actuations or less, for theprophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years ofage and over.

4 BELATACEPT.4 BELIMUMAB.4 BEMEGRIDE.4 BENACTYZINE.5 BENALAXYL.

4 BENAZEPRIL.7 BENDIOCARB exceptwhen included in Schedule 5 or 6.

6 BENDIOCARB:(a) in wettable powders containing 80 per cent or less of bendiocarb when packed in

containers or primary packs containing not less than 100 g of bendiocarb;(b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002

per cent of denatonium benzoate when packed in containers or primary packs containingnot less than 48 g of bendiocarb and labelled for use as a fly control preparation;

(c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or(d) when impregnated in plastic resin strip material containing 10 per cent or less of

bendiocarb,exceptwhen included in Schedule 5.

5 BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.4 BENDROFLUAZIDE.4 BENETHAMINE PENICILLIN.7 BENOMYL exceptin paints containing 0.5 per cent of less of benomyl.4 BENORYLATE.4 BENOXAPROFEN.4 BENPERIDOL.6 BENQUINOX.4 BENSERAZIDE.6 BENSULIDE.5 BENTAZONE.6 BENZALKONIUM CHLORIDE except:

(a) when included in Schedule 5; or(b) in preparations containing 5 per cent or less of benzalkonium chloride.

5 BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkoniumchloride exceptin preparations containing 5 per cent or less of benzalkonium chloride.

4 BENZATHINE PENICILLIN.7 BENZENE (excluding its derivatives) except:

(a) preparations containing 15 mL/L or less of benzene; or(b) petrol containing 50 mL/L or less of benzene.

4 BENZHEXOL.4 BENZILONIUM.4 BENZOCAINE except:

(a) when included in Schedule 2;(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances;or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosageunit.


12/100

TG147/97 Page 12of 100

2 BENZOCAINE in preparations for topical use other than eye drops:(a) containing 10 per cent or less or total local anaesthetic substances, exceptin dermal

preparations containing 2 per cent or less of total local anaesthatic substances; or(b) in divided preparations containing 200 mg or less of total local anaesthetic substances

per dosage unit, exceptin lozenges containing 30 mg or less of total local anaestheticsubstances per dosage unit.

4 BENZODIAZEPINE derivatives exceptwhen separately specified in these Schedules. (AppendixA, Appendix D)

5 BENZOFENAP.5 BENZOYL PEROXIDE except:(a) when included in Schedule 2 or 4; or(b) in preparations containing 5 per cent or less of benzoyl peroxide.

4 BENZOYL PEROXIDE in preparations for human therapeutic use except:

(a) when included in Schedule 2; or(b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

2 BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per centor less of benzoyl peroxide exceptin preparations containing 5 per cent or less of benzoylperoxide.

4 BENZPHETAMINE. (Appendix D)4 BENZTHIAZIDE.

4 BENZTROPINE (benzatropine). (Appendix A)4 BENZYDAMINE except:

(a) when included in Schedule 2; or(b) in preparations for dermal use.

2 BENZYDAMINE in preparations for topical use, exceptin preparations for dermal use.6 6-BENZYLADENINE exceptin preparations containing 2 per cent or less of 6-benzyladenine.8 BENZYLMORPHINE.4 BENZYLPENICILLIN.2 BEPHENIUM SALTS.4 BEPRIDIL.4 BERACTANT.5 BERGAMOT OIL except:

(a) when steam distilled or rectified;(b) in preparations for internal use;(c) in preparations containing 0.4 per cent or less of bergamot oil;(d) in soaps or bath or shower gels that are washed off the skin;(e) in preparations other than medicines for human therapeutic use, when packed in

containers labelled with the statement:Application to the skin may increase sensitivity to sunlight; or

(f) in medicines for human therapeutic use, when packed in containers and compliant withthe requirements of the Required Advisory Statements for Medicine Labels.

6 BERYLLIUM.4 BESIFLOXACIN HYDROCHLORIDE.7 BETACYFLUTHRIN exceptwhen included in Schedule 5 or 6.6 BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin

exceptwhen included in Schedule 5.5 BETACYFLUTHRIN:

(a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or(b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

6 BETA-CYPERMETHRIN.4 BETAHISTINE.4 BETAMETHASONE.4 BETAXOLOL.4 BETHANECHOL CHLORIDE.4 BETHANIDINE.

4 BEVACIZUMAB.4 BEVANTOLOL.4 BEXAROTENE.4 BEZAFIBRATE.8 BEZITRAMIDE.


13/100

TG147/97 Page 13of 100

6 BHC (excluding lindane).4 BICALUTAMIDE.7 BIFENTHRIN except:

(a) when included in Schedule 6; or(b) in preparations containing 0.5 per cent or less of bifenthrin.

6 BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin exceptin preparations

containing 0.5 per cent or less of bifenthrin.7 BIFLUORIDES (including ammonium, potassium, and sodium salts) exceptwhen included in

Schedule 5 or 6.6 BIFLUORIDES (including ammonium, potassium, and sodium salts) in preparations containing 3per cent or less of total bifluorides exceptwhen included in Schedule 5.

5 BIFLUORIDES (including ammonium, potassium, and sodium salts) in preparations containing0.3 per cent or less of total bifluorides.

4 BIFONAZOLE except:(a) when included in Schedule 2;(b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment

of the scalp; or(a) in preparations for dermal use for the treatment of tinea pedis.

2 BIFONAZOLE in preparations for dermal use except:(a) in preparations containing 1 percent or less of bifonazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.4 BIMATOPROST.6 BIOALLETHRIN except:

(a) when included in Schedule 5; or(b) in preparations containing 1 per cent or less of bioallethrin.

5 BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin exceptinpreparations containing 1 per cent or less of bioallethrin.

5 BIORESMETHRIN exceptin preparations containing 10 per cent or less of bioresmethrin.4 BIPERIDEN.4 BISMUTH COMPOUNDS for cosmetic use, except:

(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5per cent or less; or

(b) bismuth oxychloride.4 BISMUTH COMPOUNDS for human therapeutic use, exceptbismuth formic iodide or bismuth

subiodide in dusting powders containing 3 per cent or less of bismuth.4 BISOPROLOL.5 BISPYRIBAC exceptin preparations containing 10 per cent or less of bispyribac.

6 BITHIONOL for treatment of animals.7 BITHIONOL for human therapeutic use.4 BIVALIRUDIN.

BLEACHES - see CHLORINATING COMPOUNDS4 BLEOMYCIN.

Exempt BLOOD (WHOLE) AND BLOOD COMPONENTS exceptwhen separately specified in theseSchedules.

4 BOCEPREVIR4 BOLANDIOL. (Appendix B, Appendix D)4 BOLASTERONE. (Appendix B, Appendix D)4 BOLAZINE. (Appendix B, Appendix D)4 BOLDENONE (dehydrotestosterone). (Appendix B, Appendix D)4 BOLENOL. (Appendix B, Appendix D)4 BOLMANTALATE. (Appendix B, Appendix D)7 BORAGO OFFICINALIS (Borage) for therapeutic use exceptthe fixed oil derived from the seeds

of Borago officinalis.5 BORIC ACID (excluding its salts) and BORAX except:

(a) when included in Schedule 4;

(b) in preparations, other than insect baits, containing 1 per cent or less of boron; or(c) in hand cleaning preparations.4 BORON, including boric acid and borax, for human therapeutic use except:

(a) in preparations for internal use containing 6 mg or less of boron per recommended dailydose;


14/100

TG147/97 Page 14of 100

(b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not forpaediatric or antifungal use; or

(c) when present as an excipient.7 BORON TRIFLUORIDE exceptwhen included in Schedule 5 or 6.6 BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3

5 BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF

)exceptwhen included in Schedule 5.

3

4 BORTEZOMIB.).

4 BOSENTAN.4 BOTULINUM TOXINS for human use exceptwhen separately specified in these Schedules.7 BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.4 BRETYLIUM TOSYLATE.4 BRIMONIDINE.4 BRINZOLAMIDE.7 BRODIFACOUM exceptwhen included in Schedule 6.

6 BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.7 BROMADIOLONE exceptwhen included in Schedule 6.6 BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMATE - see individual bromates.4 BROMAZEPAM. (Appendix A, Appendix D)

7 BROMETHALIN exceptwhen included in Schedule 6.6 BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.2 BROMHEXINE.4 BROMIDES, inorganic, for therapeutic use exceptwhen separately specified in these

Schedules.7 BROMINE (excluding its salts and derivatives).4 BROMOCRIPTINE.6 BROMOFORM exceptwhen included in Schedule 4.4 BROMOFORM for therapeutic use.6 BROMOPHOS.6 BROMOPHOS-ETHYL.6 BROMOXYNIL.

4 BROMPHENIRAMINE exceptwhen included in Schedule 2 or 3. (Appendix A)3 BROMPHENIRAMINE in oral preparations except:

(a) when included in Schedule 2; or(b) for the treatment of children under 2 years of age. (Appendix A)

2 BROMPHENIRAMINE when combined with one or more other therapeutically active substancesin oral preparations when:(a) at least one of the other therapeutically active substances is a sympathomimetic

decongestant; or(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and

night doses are in the same immediate container or immediate wrapper,exceptin preparations for the treatment of children under 2 years of age. (Appendix A)

6 BROMUCONAZOLE exceptwhen included in Schedule 5.

5 BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.4 BROMVALETONE.6 BROTIANIDE.7 BRUCINE exceptin alcohol containing 0.02 per cent or less of brucine as a denaturant.4 BRUGMANSIA spp.4 BUCLIZINE exceptwhen included in Schedule 3. (Appendix A)3 BUCLIZINE in oral preparations. (Appendix A)7 BUCLOSAMIDE for therapeutic use.4 BUDESONIDE exceptwhen included in Schedule 2.2 BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per

actuation when the maximum recommended daily dose is no greater than 400 micrograms and

when packed in a primary pack containing 200 actuations or less, for the prophylaxis ortreatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.4 BUFEXAMAC except:

(a) in preparations for dermal use containing 5 per cent or less of bufexamac; or(b) in suppositories.


15/100

TG147/97 Page 15of 100

4 BUMETANIDE.6 BUNAMIDINE.7 BUNIODYL SODIUM for therapeutic use.4 BUPHENINE.4 BUPIVACAINE.8 BUPRENORPHINE. (Appendix A, Clause 123)5 BUPROFEZIN exceptin preparations containing 40 per cent or less of buprofezin.4 BUPROPION.

4 BUSERELIN.4 BUSPIRONE.4 BUSULPHAN.4 BUTACAINE.6 BUTACARB.7 1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for

domestic use.5 BUTHIDAZOLE.8 BUTOBARBITONE. (Appendix A)4 BUTOCONAZOLE exceptwhen included in Schedule 3.3 BUTOCONAZOLE in preparations for vaginal use.8 BUTORPHANOL.

6 BUTOXYCARBOXIM exceptwhen included in Schedule 5.5 BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.6 2-BUTOXYETHANOL and its ACETATES exceptin preparations containing 10 per cent or less

of such substances.6 2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER.4 BUTRACONAZOLE.5 BUTRALIN.5 BUTROXYDIM.4 BUTYL AMINOBENZOATE exceptin dermal preparations containing 2 per cent or less of total

local anaesthetic substances.4 BUTYLCHLORAL HYDRATE.4 BUTYL NITRITE.

6 BUTYRIC ACID in preparations for use as insect lures.4 CABAZITAXEL.4 CABERGOLINE.7 CACALIA spp. for therapeutic use.7 CACODYLIC ACID except:

(a) when included in Schedule 6; or(b) in animal feeds containing 75 g/tonne or less of arsenic.

6 CACODYLIC ACID:(a) in animal feed premixes containing 4 per cent or less of arsenic; or(b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

6 CADMIUM COMPOUNDS except:(a) when included in Schedule 4; or(b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-

volatile content of the paint or tinter.4 CADMIUM COMPOUNDS for human therapeutic use.7 CADUSAFOS exceptwhen included in Schedule 6.6 CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated

cadusafos.CAFFEINE - see entries for ASPIRIN, PARACETAMOL and SALICYLAMIDE.

6 CAJUPUT OIL except:(a) in medicines for human therapeutic use, when packed in containers having a nominal

capacity of 15 mL or less fitted with a restricted flow insert and compliant with the

requirements of the Required Advisory Statements for Medicine Labels;(b) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closureand compliant with the requirements of the Required Advisory Statements for MedicineLabels;


16/100

TG147/97 Page 16of 100

(c) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity 15 mL or less fitted with a restricted flow insert andlabelled with the warnings:KEEP OUT OF THE REACH OF CHILDREN; andNOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity of 25 mL or less fitted with a restricted flow insertand a child-resistant closure, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; andNOT TO BE TAKEN;(e) in preparations containing 25 per cent or less of cajuput oil; or(f) in oils containing 25 per cent or less of cajuput oil.

7 CALCIFEROL for use as a rodenticide exceptwhen included in Schedule 6.6 CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.4 CALCIPOTRIOL.4 CALCITONIN.4 CALCITRIOL.4 CALCIUM CARBIMIDE for therapeutic use.4 CALCIUM POLYSTYRENE SULPHONATE.4 CALOTROPIS GIGANTEA.

4 CALOTROPIS PROCERA.4 CALUSTERONE. (Appendix B, Appendix D)6 CAMBENDAZOLE.6 CAMPHOR except:

(a) when included in Schedule 4 or 5;(b) when enclosed in an inhaler device which prevents ingestion of its contents;(c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;(d) in liquid preparations containing 2.5 per cent or less of camphor;(e) in essential oils when the camphor is present as a natural component of the oil:

(i) in medicines for human therapeutic use, packed in containers having a nominalcapacity of 15 mL or less fitted with a restricted flow insert and compliant with therequirements of the Required Advisory Statements for Medicine Labels;

(ii) in medicines for human therapeutic use, packed in containers having a nominalcapacity of 25 mL or less fitted with a restricted flow insert and a child-resistantclosure and compliant with the requirements of the Required Advisory Statementsfor Medicine Labels;

(iii) in essential oils other than medicines for human therapeutic use, packed incontainers having a nominal capacity 15 mL or less fitted with a restricted flowinsert, and labelled with the warnings:KEEP OUT OF THE REACH OF CHILDREN; andNOT TO BE TAKEN;

(iv) in essential oils other than medicines for human therapeutic use, packed incontainers having a nominal capacity of 25 mL or less fitted with a restricted flowinsert and a child-resistant closure, and labelled with the warnings:KEEP OUT OF REACH OF CHILDREN; andNOT TO BE TAKEN;

(f) in rosemary oil, sage oil (Spanish), or lavindin oil as such.5 CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor

except:(a) in medicines for human therapeutic use, in essential oils packed in containers having a

nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with therequirements of the Required Advisory Statements for Medicine Labels;

(b) in preparations other than medicines for human therapeutic use, in essential oils packedin containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert,and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; andNOT TO BE TAKEN;(c) in rosemary oil, sage oil (Spanish), or lavindin oils; or(d) in preparations containing 2.5 per cent or less of camphor.

4 CAMPHORATED OIL for therapeutic use.


17/100

TG147/97 Page 17of 100

4 CAMPHOTAMIDE.4 CANAGLIFLOZIN.4 CANAKINUMAB.4 CANDESARTAN CILEXETIL.4 CANDICIDIN.4 CANINE TICK ANTI-SERUM.4 CANTHARIDIN.4 CAPECITABINE.

4 CAPREOMYCIN.7 CAPTAFOL.6 CAPTAN.4 CAPTODIAME.4 CAPTOPRIL.4 CAPURIDE.4 CARAMIPHEN.4 CARBACHOL.7 CARBADOX.4 CARBAMAZEPINE.6 CARBAMIDE PEROXIDE except:


(b) in other preparations containing 9 per cent or less of carbamide peroxide.7 CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations

containing more than 18 per cent of carbamide peroxide except in preparations manufacturedfor and supplied solely by registered dental practitioners as part of their dental practice. (Clause20)

5 CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxideexceptin preparations containing 9 per cent or less of carbamide peroxide.

6 CARBARYL exceptwhen included in Schedule 4 or 5.5 CARBARYL:

(a) in preparations containing 10 per cent or less of carbaryl exceptwhen included in

Schedule 4; or(b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

4 CARBARYL for human therapeutic use.4 CARBAZOCHROME.7 CARBENDAZIM exceptin paints, jointing compounds and sealants containing 0.1 per cent or

less of carbendazim.4 CARBENICILLIN.4 CARBENOXOLONE for internal use.2 CARBETAPENTANE exceptin preparations containing 0.5 per cent or less of carbetapentane.

4 CARBETOCIN.4 CARBIDOPA.4 CARBIMAZOLE.2 CARBOCISTEINE.4 CARBOCROMEN.7 CARBOFURAN.6 CARBON DISULFIDE.7 CARBON TETRACHLORIDE exceptin chlorinated rubber based paint containing 1 per cent or

less of carbon tetrachloride.CARBONIC ANHYDRASE INHIBITORS - see individual entries.

7 CARBONYL SULFIDE when packed and labelled for use as a fumigant.7 CARBOPHENOTHION.4 CARBOPLATIN.4 CARBOPROST.7 CARBOSULFAN.4 CARBROMAL.

4 CARBUTAMIDE.4 CARBUTEROL.8 CARFENTANYL.4 CARINDACILLIN.4 CARISOPRODOL.


18/100

TG147/97 Page 18of 100

4 CARMUSTINE.4 CARNIDAZOLE.4 CARPROFEN.4 CARVEDILOL.4 CASPOFUNGIN.5 CASSIA OIL except:

(a) in food additives;(b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil;

or(c) in other preparations containing 2 per cent or less of cassia oil.6 CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic

use exceptin wash-off preparations containing 1 per cent or less of castor oil, monomaleate.CATALIN - see PIRFENOXONE SODIUM.

4 CATHINE. (Appendix D)4 CATUMAXOMAB.4 CEFACETRILE.4 CEFACLOR.4 CEFADROXIL.4 CEFALORIDINE.4 CEFAMANDOLE.

4 CEFAPIRIN.4 CEFAZOLIN.4 CEFEPIME.4 CEFETAMET.4 CEFIXIME.4 CEFODIZIME.4 CEFONICID.4 CEFOPERAZONE.4 CEFOTAXIME.4 CEFOTETAN.4 CEFOTIAM.4 CEFOVECIN for veterinary use.

4 CEFOXITIN.4 CEFPIROME.4 CEFPODOXIME.4 CEFQUINOME.4 CEFSULODIN.4 CEFTAROLINE FOSAMIL.4 CEFTAZIDIME.4 CEFTIBUTEN.4 CEFTIOFUR.4 CEFTRIAXONE.4 CEFUROXIME.4 CELECOXIB.4 CELIPROLOL.4 CEPHAELIS ACUMINATA (ipecacuanha) exceptin preparations containing 0.2 per cent or less

of emetine.4 CEPHAELIS IPECACUANHA exceptin preparations containing 0.2 per cent or less of emetine.4 CEPHALEXIN.4 CEPHALONIUM.4 CEPHALOTHIN.4 CEPHRADINE.

Exempt CERAMICS.4 CERIVASTATIN.4 CERTOLIZUMAB PEGOL.

4 CERULETIDE.4 CETIRIZINE except(a) when included in Schedule 2; or(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults

and children 12 years of age and over when:


19/100

TG147/97 Page 19of 100

(i) in a primary pack containing not more than 5 days supply; and(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

2 CETIRIZINE in preparations for oral use exceptin divided preparations for the treatment ofseasonal allergic rhinitis in adults and children 12 years of age and over when:(a) in a primary pack containing not more than 5 days supply and;(b) labelled with a recommended daily dose not exceeding 10mg of cetirizene..

4 CETRORELIX.4 CETUXIMAB.

Exempt CHEMISTRY SETS for toy and educational use, when complying with the requirements ofAustralian Standard AS 8124.4-2003 Safety of toys - Part 4: Experimental sets for chemistry andrelated activities.

4 CHENODEOXYCHOLIC ACID.2 CHLOPHEDIANOL.4 CHLORAL FORMAMIDE.4 CHLORAL HYDRATE exceptin preparations for topical use containing 2 per cent or less of

chloral hydrate. (Appendix A)4 CHLORALOSE exceptwhen included in Schedule 6.6 CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.4 CHLORAMBUCIL.4 CHLORAMPHENICOL exceptwhen included in Schedule 3.

3 CHLORAMPHENICOL for ophthalmic use only.4 CHLORANDROSTENOLONE. (Appendix B, Appendix D)4 CHLORAZANIL.3 CHLORBUTOL in preparations for human use except:

(a) when included in Schedule 2; or(b) in preparations containing 0.5 per cent or less of chlorbutol.

2 CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol,exceptin preparations containing 0.5 per cent or less of chlorbutol.

4 CHLORCYCLIZINE.6 CHLORDANE.7 CHLORDECONE.4 CHLORDIAZEPOXIDE. (Appendix A, Appendix D)

7 CHLORDIMEFORM.5 CHLORFENAC.5 CHLORFENAPYR in preparations containing 0.5 per cent or less of chlorfenapyr.7 CHLORFENAPYR exceptwhen included in Schedules 5 or 6.6 CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr exceptwhen

included in Schedule 5.6 CHLORFENETHOL.5 CHLORFENSON.7 CHLORFENVINPHOS.7 CHLORHEXIDINE except:

(a) when included in Schedule 5 or 6;(b) in preparations containing 1 per cent or less of chlorhexidine; or(c) when in solid preparations.

6 CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine except:(a) when included in Schedule 5;(b) in preparations containing 1 per cent or less of chlorhexidine; or(c) when in solid preparations.

5 CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine except:(a) in preparations containing 1 per cent or less of chlorhexidine; or(b) when in solid preparations.

6 CHLORINATING COMPOUNDS except:(a) when included in Schedule 5;(b) when separately specified in these Schedules;

(c) sodium hypochlorite preparations with a pH of less than 11.5;(d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent ofavailable chlorine when labelled with the statements:WARNING- Ensure adequate ventilation when using. Vapour may be harmful. May giveoff dangerous gas if mixed with other products;


20/100

TG147/97 Page 20of 100

(e) in liquid preparations containing less than 2 per cent of available chlorine; or(f) in other preparations containing 4 per cent or less of available chlorine.

5 CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, except:(a) when separately specified in these Schedules;(b) sodium hypochlorite preparations with a pH of less than 11.5;(c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of

available chlorine when labelled with the statements:WARNING- Ensure adequate ventilation when using. Vapour may be harmful. May give

off dangerous gas if mixed with other products;(d) liquid preparations containing less than 2 per cent of available chlorine; or(e) other preparations containing 4 per cent or less of available chlorine.

7 CHLORINE (excluding its salts and derivatives).6 CHLORMEQUAT.4 CHLORMERODRIN.4 CHLORMETHIAZOLE. (Appendix A)4 CHLORMEZANONE.5 CHLORNIDINE.5 CHLOROCRESOL exceptin preparations containing 3 per cent or less of chlorocresol.6 CHLOROFORM except:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of chloroform.2 CHLOROFORM in preparations for therapeutic use except:

(a) when included in Schedule 4; or(b) in preparations containing 0.5 per cent or less of chloroform.

4 CHLOROFORM for use in anaesthesia.6 alpha-CHLOROHYDRIN.4 4-CHLOROMETHANDIENONE. (Appendix B, Appendix D)7 CHLOROMETHIURON.7 5-CHLORO-3-METHYL-4-NITROPYRAZOLE.6 CHLOROPHACINONE.6 (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL

(uniconazole-p) exceptin preparations containing 5 per cent or less of (E)-(S)-1-(4-

chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.4 2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.7 CHLOROPICRIN exceptwhen included in Schedule 6.6 CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.4 CHLOROQUINE.6 CHLOROTHALONIL exceptin water-based paint containing 0.5 per cent or less of

chlorothalonil.4 CHLOROTHIAZIDE.7 4-CHLORO-o-TOLUIDINE.4 CHLOROTRIANISENE.4 CHLOROXYDIENONE. (Appendix B, Appendix D)4 CHLORPHENIRAMINE exceptwhen included in Schedule 2 or 3. (Appendix A)3 CHLORPHENIRAMINE in oral preparations except:


2 CHLORPHENIRAMINE when combined with one or more other therapeutically activesubstances in oral preparations when:(a) at least one of the other therapeutically active substances is a sympathomimetic

decongestant; or(b) in a day-night pack containing chlorpheniramine in the bed-time dose, where the day and

night doses are in the same immediate container or immediate wrapper,exceptin preparations for the treatment of children under 2 years of age. (Appendix A)

4 CHLORPHENTERMINE. (Appendix A)

4 CHLORPROMAZINE. (Appendix A)4 CHLORPROPAMIDE.5 CHLORPROPHAM.4 CHLORPROTHIXENE.6 CHLORPYRIFOS except:


21/100

TG147/97 Page 21of 100

(a) when included in Schedule 5; or(b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

5 CHLORPYRIFOS:(a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;(b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos;

or(c) in other preparations containing 5 per cent or less of chlorpyrifos,exceptin prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

6 CHLORPYRIFOS-METHYL.4 CHLORQUINALDOL for human topical use.5 CHLORSULFURON.4 CHLORTETRACYCLINE exceptwhen included in Schedule 5.5 CHLORTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or(b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the

treatment of ornamental caged birds or ornamental fish only.5 CHLORTHAL-DIMETHYL.4 CHLORTHALIDONE.6 CHLORTHIAMID.7 CHLORTHIOPHOS.

4 CHLORZOXAZONE.4 CHOLERA VACCINE.4 CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHORIONIC ANTIBODY - see HUMAN CHORIONIC GONADOTROPHIN ANTIBODY.6 CHROMATES (including dichromates) exceptin paints or tinters containing 5 per cent or less of

chromium as the ammonium, barium, potassium, sodium, strontium or zinc chromate calculatedon the non-volatile content of the paint or tinter.

6 CHROMIUM TRIOXIDE (excluding its salts and derivatives).4 CHYMOPAPAIN for human therapeutic use.4 CICLACILLIN.4 CICLESONIDE.4 CICLOPIROX except:

(a) when included in Schedule 2 or 3; or(b) in preparations for the treatment of tinea pedis.

3 CICLOPIROX in preparations for dermal use and for application to the nails except:(a) when included in Schedule 2; or(b) in preparations for the treatment of tinea pedis.

2 CICLOPIROX:(a) in preparations for dermal use containing 2 per cent or less of ciclopirox exceptinpreparations for the treatment of tinea pedis; or(b) in preparations for application to the nails containing 8 per cent or less of ciclopirox.

4 CIDOFOVIR.4 CILASTATIN.4 CILAZAPRIL.4 CILOSTAZOL.4 CIMETIDINE exceptwhen included in Schedule 3.3 CIMETIDINE in a primary pack containing not more than 14 days supply.4 CINACALCET.4 CINCHOCAINE exceptwhen included in Schedule 2.2 CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or

less of total local anaesthetic substances.7 CINCHOPHEN and its derivatives for therapeutic use.6 CINEOLE except:

(a) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 15 mL or less fitted with a restricted flow insert and compliant with the

requirements of the Required Advisory Statements for Medicine Labels;(b) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closureand compliant with the requirements of the Required Advisory Statements for MedicineLabels;


22/100

TG147/97 Page 22of 100


(d) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity of 25 mL or less fitted with a restricted flow insertand a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; andNOT TO BE TAKEN;(e) in preparations containing 25 per cent or less of cineole;(f) in oils containing 25 per cent or less of cineole; or(g) in rosemary oil or camphor oil (white).

5 CINMETHYLIN.2 CINNAMEDRINE.5 CINNAMON BARK OIL except:

(a) in food additives; or(b) in preparations containing 2 per cent or less of cinnamon bark oil.

6 CINNAMON LEAF OIL except:(a) in medicines for human therapeutic use, when packed in containers having a nominal


(b) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 25 mL or less fitted with a restricted flow insert and a child resistant closureand compliant with the requirements of the Required Advisory Statements for MedicineLabels;


(d) in preparations other than medicines for human therapeutic use, when packed in

containers having a nominal capacity of 25 mL or less fitted with a restricted flow insertand a child-resistant closure, and labelled with the warnings:KEEP OUT OF REACH OF CHILDREN; andNOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cinnamon leaf oil.4 CINOXACIN.4 CIPROFLOXACIN.4 CISAPRIDE.4 CISATRACURIUM BESYLATE.4 CISPLATIN.4 CITALOPRAM.4 CLADRIBINE.4 CLANOBUTIN.4 CLARITHROMYCIN.4 CLAVULANIC ACID.4 CLEMASTINE exceptwhen included in Schedule 3.3 CLEMASTINE in preparations for oral use.4 CLEMIZOLE.4 CLENBUTEROL.5 CLETHODIM.4 CLEVIDIPINE.4 CLIDINIUM BROMIDE.6 CLIMBAZOLE except:

(a) when included in Schedule 5; or(b) in preparations containing 2 per cent or less of climbazole.5 CLIMBAZOLE in preparations containing 40 per cent or less of climbazole exceptin

preparations containing 2 per cent or less of climbazole.4 CLINDAMYCIN.


23/100

TG147/97 Page 23of 100

7 CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal useexceptwhen being used solely for experimental purposes in humans and such use:(a) is in accordance with an approval granted under paragraph 19(1)(b), and the

requirements of subsection 19(4A), of the Therapeutic Goods Act 1989 (as amendedfrom time to time) otherwise known as the Clinical Trial Exemption (CTX) scheme; or

(b) is in accordance with the requirements of subsection 18(1) of the Therapeutic Goods Act1989 and Regulation 12(1A) of the Therapeutic Goods Regulations 1990 (as amendedfrom time to time) otherwise known as the Clinical Trial Notification (CTN) scheme.

4 CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical useexceptwhen separately specified in this Schedule.4 CLOBAZAM. (Appendix D)4 CLOBETASOL.4 CLOBETASONE (clobetasone-17-butyrate) exceptwhen included in Schedule 3.

3 CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance inpreparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing30 g or less of the preparation.

4 CLOCORTOLONE.6 CLODINAFOP-PROPARGYL.4 CLODRONIC ACID (including sodium clodronate).4 CLOFARABINE.

4 CLOFAZIMINE.4 CLOFENAMIDE.5 CLOFENTEZINE.4 CLOFIBRATE.6 CLOMAZONE.4 CLOMIPHENE. (Clauses 37,52,60)4 CLOMIPRAMINE. (Appendix A)4 CLOMOCYCLINE.4 CLONAZEPAM (Appendix A, Appendix D)4 CLONIDINE. (Appendix A)4 CLOPAMIDE.4 CLOPIDOGREL.

4 CLOPROSTENOL.5 CLOPYRALID.5 CLOQUINTOCET-MEXYL.4 CLORAZEPATE. (Appendix A, Appendix D)4 CLOREXOLONE.4 CLORPRENALINE.5 CLORSULON.6 CLOSANTEL.4 CLOSTEBOL (4-chlorotestosterone). (Appendix B, Appendix D)6 CLOTHIANIDIN exceptwhen included in Schedule 5.5 CLOTHIANIDIN in preparations containing 20 per cent of less of clothianidin.4 CLOTRIMAZOLE except:

(a) when included in Schedule 2, 3 or 6; or(b) in preparations for dermal use for the treatment of tinea pedis.

2 CLOTRIMAZOLE for human use in dermal preparations and for application to the nails exceptinpreparations for the treatment of tinea pedis.

3 CLOTRIMAZOLE in preparations for vaginal use.6 CLOTRIMAZOLE for external treatment of animals.6 CLOVE OIL except:

(a) when included in Schedule 5;(b) in medicines for human therapeutic use, when packed in containers having a nominal


(c) in medicines for human therapeutic use, when packed in containers having a nominalcapacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closureand compliant with the requirements of the Required Advisory Statements for MedicineLabels;

(d) in preparations other than medicines for human therapeutic use, when packed in


24/100

TG147/97 Page 24of 100

containers having a nominal capacity 15 mL or less fitted with a restricted flow insert andlabelled with the warnings:KEEP OUT OF THE REACH OF CHILDREN; andNOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed incontainers having a nominal capacity of 25 mL or less fitted with a restricted flow insertand a child-resistant closure, and labelled with the warnings:KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;(f) in preparations containing 25 per cent or less of clove oil.5 CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil exceptin

preparations containing 25 per cent or less of clove oil.4 CLOXACILLIN.4 CLOZAPINE.7 COAL TAR for cosmetic use other than in therapeutic goods.4 COBALT for human therapeutic use exceptas dicobalt edetate in preparations for the treatment

of cyanide poisoning.4 COBICISTAT.8 COCAINE.6 N-COCO-1,3-DIAMINOPROPANE.

8 CODEINE exceptwhen included in Schedule 2, 3 or 4. (Appendix A)4 CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; (Appendix A)or

(b) in undivided preparations containing 1 per cent or less of codeine, (Appendix A)exceptwhen included in Schedule 2 or 3.

3 CODEINE when:(a) not combined with any other opiate substance;(b) compounded with one or more other therapeutically active substances, of which not more

than one is an analgesic substance:(i) in divided preparations containing 12 mg or less of codeine per dosage unit; or(ii) in undivided preparations containing 0.25 per cent or less of codeine;

(c) labelled with a recommended daily dose not exceeding 100 mg of codeine; and(d) in packs containing not more than 5 days of supply at the maximum dose recommended

on the label,exceptwhen included in Schedule 2.

2 CODEINE in preparations for the treatment of coughs and colds when:(a) not combined with any other opiate substance;(b) compounded with one or more other therapeutically active substances, of which at least

one is phenylephrine and not more than one is an analgesic substance:(i) in divided preparations containing 10 mg or less of codeine per dosage unit; or(ii) in undivided preparations containing 0.25 per cent of less of codeine;

(c) labelled with a recommended daily dose not exceeding 60 mg of codeine; and(d) in packs containing not more than 6 days of supply at the maximum dose recommended

on the label.8 CODEINE-N-OXIDE.4 CO-DERGOCRINE.4 COLASPASE.4 COLCHICINE.4 COLCHICUM AUTUMNALE.7 COLECALCIFEROL for use as a rodenticide.4 COLESTIPOL.4 COLFOSCERIL PALMITATE for human therapeutic use.4 COLISTIN.4 COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or(b) for cosmetic use.8 CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a

process for concentration of its alkaloids).7 CONIUM MACULATUM (coniine) for therapeutic use.


25/100

TG147/97 Page 25of 100

4 CONVALLARIA KEISKI.4 CONVALLARIA MAJALIS.6 COPPER ACETATE except:

(a) when included in Schedule 5; or(a) in preparations containing 5 per cent or less of copper acetate.

5 COPPER ACETATE in preparations containing 20 per cent or less of copper acetate except

when in preparations containing 5 per cent or less of copper acetate.Exempt COPPER COMPOUNDS in paints.

6 COPPER COMPOUNDS except:(a) when separately specified in these Schedules;(b) in preparations for human internal use containing 5 mg or less of copper per

recommended daily dose;(c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or

less;(d) in feed additives containing 1 per cent or less of copper; or(e) in other preparations containing 5 per cent or less of copper compounds.

5 COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper exceptin preparations containing 1 per cent or less of copper.

4 COPPER COMPOUNDS for human use except:(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper perrecommended daily dose; or

(c) in other preparations containing 5 per cent or less of copper compound.6 COPPER HYDROXIDE except:

(a) when included in Schedule 5; or(b) in preparations containing 12.5 per cent or less of copper hydroxide.

5 COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxideexceptin preparations containing 12.5 per cent or less of copper hydroxide.

6 COPPER NITRATE in preparations containing copper chloride for the treatment of footrot insheep.

6 COPPER OXIDES except:(a) when included in Schedule 5;

(b) in preparations for internal use;(c) in marine paints; or(d) in other preparations containing 5 per cent or less of copper oxides.

5 COPPER OXIDES in preparations containing 25 per cent or less of copper oxides except:(a) in preparations for internal use;(b) in marine paints; or(c) in other preparations containing 5 per cent or less of copper oxides.

6 COPPER OXYCHLORIDE except:(a) when included in Schedule 5; or(b) in preparations containing 12.5 per cent or less of copper oxychloride.

5 COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychlorideexceptin preparations containing 12.5 per cent or less of copper oxychloride.

6 COPPER SULFATE except:(a) when included in Schedule 5;(b) in preparations for internal use; or(c) in other preparations containing 5 per cent or less of copper sulfate.

5 COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate except:(a) in preparations for internal use; or(b) in other preparations containing 5 per cent or less of copper sulfate.

4 CORIFOLLITROPIN ALFA.4 CORONILLA spp.4 CORTICOSTERONE.4 CORTICOTROPHIN.

4 CORTISONE.7 COTARNINE for therapeutic use.4 CO-TRIMOXAZOLE.7 COUMAPHOS exceptwhen included in Schedule 6.6 COUMAPHOS:


26/100

TG147/97 Page 26of 100

(a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less ofcoumaphos; or

(b) in other preparations containing 5 per cent or less of coumaphos.4 COUMARIN for therapeutic use (excluding when present as an excipient).7 COUMATETRALYL exceptwhen included in Schedule 5 or 6.6 COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl exceptwhen

included in Schedule 5.5 COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.

5 4-CPA.7 CREOSOTE derived from beechwood.7 CREOSOTE derived from coal.6 CREOSOTE derived from wood other than beechwood except:

(a) when included in Schedule 2;(b) in preparations for human therapeutic use containing 10 per cent or less of creosote

(derived from wood other than beechwood); or(c) in other preparations containing 3 per cent or less of phenols and homologues of phenol

boiling below 220o

2 CREOSOTE derived from wood other than beechwood for human therapeutic use, exceptinC.

preparations containing 10 per cent or less of creosote derived from wood other thanbeechwood.

4 CRIZOTINIB.4 CROFELEMER.

7 CROTALARIA spp. for therapeutic use.7 CROTON TIGLIUM for therapeutic use.6 CROTOXYPHOS.6 CRUFOMATE.4 CRYSTAL VIOLET for human use exceptwhen used as a dermal marker.4 CUPRIMYXIN.4 CURARE.

CURING AGENTS for resins - see ANHYDRIDES, ORGANIC ACID also AMINES.6 CYANAMIDE.5 CYANATRYN.

6 CYANAZINE.7 CYANIDES, metallic except:

(a) ferricyanides;(b) ferrocyanides; or(c) when separately specified in these Schedules. (Clause 20)

5 CYANOACRYLATE ESTERS in contact adhesives except:(a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoidbreathing vapour. Bonds on contact. Should fingers stick together apply a solvent such asacetone to contact areas then wash off with water. Do not use solvents near eyes or openwounds. In case of eye contact immediately flush with water; or

(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylateesters:(i) labelled with the approved name or trade name of the poison, the quantity and the

warning:Can cause eye injury. Instantly bonds skin. and

(ii) enclosed in a primary pack labelled with the warning:KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes andavoid breathing vapour. Bonds on contact. Should fingers stick together apply asolvent such as acetone to contact areas then wash off with water. Do not usesolvents near eyes or open wounds. In case of eye contact immediately flush withwater.

7 CYANOGEN.

8 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).5 CYANTRANILIPROLE.5 CYANURIC ACID (excluding its salts and derivatives).5 CYAZOFAMID.4 CYCLANDELATE.


27/100

TG147/97 Page 27of 100

6 CYCLANILIDE.4 CYCLIZINE exceptwhen included in Schedule 3. (Appendix A)3 CYCLIZINE in preparations for oral use. (Appendix A)8 CYCLOBARBITONE. (Appendix A)4 CYCLOBENZAPRINE.4 CYCLOFENIL. (Clauses 37,52,60)5 CYCLOHEXANONE PEROXIDE.4 CYCLOHEXIMIDE.

6 N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.4 CYCLOPENTHIAZIDE.4 CYCLOPENTOLATE.4 CYCLOPHOSPHAMIDE.4 CYCLOPROPANE for therapeutic use.5 CYCLOPROTHRIN exceptin preparations containing 10 per cent or less of cycloprothrin.4 CYCLOSERINE. (Appendix A)4 CYCLOSPORIN.4 CYCLOTHIAZIDE.5 CYCLOXYDIM.4 CYCRIMINE.5 CYFLUFENAMID.

6 CYFLUTHRIN except:(a) when included in Schedule 5; or(b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.

5 CYFLUTHRIN:(a) in wettable powders containing 10 per cent or less of cyfluthrin;(b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or(c) in emulsions containing 5 per cent or less of cyfluthrin.

5 CYHALOFOP-BUTYL.7 CYHALOTHRIN (aRS,IR,cis,Z):(aRS,IS,cis,Z)=50:50.7 CYHEXATIN.4 CYMARIN.5 CYMIAZOLE.

7 CYNOGLOSSUM spp. for therapeutic use.6 CYOMETRINIL.6 CYPERMETHRIN exceptwhen included in Schedule 5.5 CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.6 CYPHENOTHRIN exceptwhen included in Schedule 5.

5 CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.5 CYPROCONAZOLE exceptin preparations containing 10 per cent or less of cyproconazole.

5 CYPRODINIL.4 CYPROHEPTADINE exceptwhen included in Schedule 3. (Appendix A)3 CYPROHEPTADINE in oral preparations. (Appendix A)4 CYPROTERONE.6 CYSTEAMINE for cosmetic use except:

(a) when included in Schedule 5; or(b) in preparations containing 1 per cent or less of cysteamine.

5 CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine exceptinpreparations containing 1 per cent or less of cysteamine.

4 CYSTEAMINE for human therapeutic use. (Appendix A)4 CYTARABINE.6 CYTHIOATE exceptwhen included in Schedule 5.5 CYTHIOATE for the treatment of animals:

(a) in divided preparations containing 30 mg or less of cythioate per dosage unit whenpacked in blister or strip packaging or in a container with a child-resistant closure; or

(b) in undivided preparations containing 5 per cent or less of cythioate.

6 2,4-D exceptwhen included in Schedule 5.5 2,4-D in preparations containing 20 per cent or less of 2,4-D.4 DABIGATRAN.4 DACARBAZINE.4 DACLIZUMAB.


28/100

TG147/97 Page 28of 100

4 DACTINOMYCIN.4 DALFOPRISTIN.4 DALTEPARIN (including dalteparin sodium).5 DAMINOZIDE.4 DANAPAROID (including danaparoid sodium).4 DANAZOL.4 DANTHRON for human use.4 DANTROLENE. (Appendix A)

4 DAPOXETINE.4 DAPAGLIFLOZIN.4 DAPSONE.4 DAPTOMYCIN.4 DARBEPOETIN.4 DARIFENACIN.4 DARUNAVIR.4 DASATINIB.4 DATURA spp. except:

(a) when included in Schedule 2; or(b) when separately specified in this Schedule.

2 DATURA spp. for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloidswhen labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and arecommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids perdosage unit when labelled with a recommended daily dose of 1.2 mg or less of totalsolanaceous alkaloids;

exceptwhen separately specified in these Schedules.4 DATURA STRAMONIUM (stramonium) except:

(a) when included in Schedule 2; or(b) when separately specified in this Schedule.

2 DATURA STRAMONIUM (stramonium) for oral use when:(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids

when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and arecommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids perdosage unit when labelled with a recommended daily dose of 1.2 mg or less of totalsolanaceous alkaloids,

exceptfor smoking or burning.4 DATURA TATULA (stramonium) except:

(a) when included in Schedule 2; or(b) for smoking or burning.

2 DATURA TATULA (stramonium) for oral use:(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids

when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and arecommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids perdosage unit when labelled with a recommended daily dose of 1.2 mg or less of totalsolanaceous alkaloids,

exceptfor smoking or burning.

4 DAUNORUBICIN.6 DAZOMET.5 2,4-DB.4 DEANOL.4 DEBRISOQUINE.4 DECAMETHONIUM.

5 DECOQUINATE.4 DEFERASIROX.4 DEFERIPRONE.4 DEFLAZACORT.4 DEGARELIX.


29/100

TG147/97 Page 29of 100

4 DEHYDROCHLOROMETHYLTESTOSTERONE. (Appendix B, Appendix D)4 DEHYDROCORTICOSTERONE.4 DELAVIRDINE (includes delavirdine mesylate).2 DELPHINIUM STAPHISAGRIA exceptin preparations containing 0.2 per cent or less of

delphinium staphisagria.7 DELTAMETHRIN except:

(a) when included in Schedule 5 or 6; or(b) when in preparations containing 0.1 per cent or less of deltamethrin.

6 DELTAMETHRIN:(a) in aqueous preparations containing 25 per cent or less of deltamethrin when no organicsolvent, other than 10 per cent or less of a glycol, is present;

(b) in wettable granular preparations containing 25 per cent or less of deltamethrin;(c) in water-dispersible tablets each containing 500 mg or less of deltamethrin; or(d) in emulsifiable concentrations containing 11 per cent or less of deltamethrin in a solvent

containing 40 per cent or less of acetophenone and 45 per cent or less of liquidhydrocarbons; or

(e) in other preparations containing 3 per cent or less of deltamethrin,exceptwhen included in Schedule 5 or in preparations containing 0.1 per cent or less ofdeltamethrin.

5 DELTAMETHRIN:

(a) when impregnated in plastic resin strip material containing 4 per cent or less ofdeltamethrin.

(b) in aqueous preparations containing 5 per cent or less of deltamethrin when no organicsolvent other than a glycol is present;

(c) in wettable granular preparations containing 25 per cent or less of deltamethrin whenpacked in child-resistant packaging each containing 3 grams or less of the formulation;

(d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or

(e) in other preparations containing 0.5 per cent or less of deltamethrin,exceptin preparations containing 0.1 per cent or less of deltamethrin.

4 DEMBREXINE exceptwhen included Schedule 5.5 DEMBREXINE in oral preparations for the treatment of animals.

4 DEMECARIUM.4 DEMECLOCYCLINE.7 DEMETON.7 DEMETON-O-METHYL.7 DEMETON-S-METHYL.4 DENOSUMAB.4 DEOXYCORTONE.4 DEOXYRIBONUCLEASE except:

(a) when separately specified in this Schedule; or(b) for external use.

4 DERACOXIB.6 DERQUANTEL.5 2,4-DES.4 DESFERRIOXAMINE.4 DESFLURANE.4 DESIPRAMINE. (Appendix A)4 DESIRUDIN.4 DESLANOSIDE.4 DESLORATADINE exceptwhen included in Schedule 2.2 DESLORATADINE in preparations for oral use.4 DESLORELIN.4 DESMOPRESSIN. (D.D.A.V.P.)4 DESOGESTREL.

4 DESONIDE.4 DESOXYMETHASONE.4 DESVENLAFAXINE.4 DETOMIDINE.4 DEXAMETHASONE.


30/100

TG147/97 Page 30of 100

8 DEXAMPHETAMINE. (Clauses 84,90,98,101,122, Appendix A)4 DEXCHLORPHENIRAMINE exceptwhen included in Schedule 2 or 3. (Appendix A)3 DEXCHLORPHENIRAMINE in oral preparations except:


2 DEXCHLORPHENIRAMINE when combined with one or more other therapeutically activesubstances in oral preparations when:(a) at least one of the other therapeutically active substances is a sympathomimetic

decongestant; or(b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the dayand night doses are in the same immediate container or immediate wrapper,

exceptin preparations for the treatment of children under 2 years of age. (Appendix A)4 DEXFENFLURAMINE.4 DEXMEDETOMIDINE.

Exempt DEXTRANS, GELATIN SUCCINYLATED & ETHERIFIED STARCHES used as plasmasubstitutes/ blood volume expanders.

4 DEXTROMETHORPHAN (excluding its stereoisomers) exceptwhen included in Schedule 2.2 DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600

mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less ofdextromethorphan.

8 DEXTROMORAMIDE. (Appendix A, Clause 123)8 DEXTROPROPOXYPHENE exceptwhen included in Schedule 4. (Appendix A)

4 DEXTROPROPOXYPHENE:(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage

unit; or(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.(Appendix A, Appendix D)

4 DEXTRORPHAN (excluding its stereoisomers).5 DIAFENTHIURON.7 DIALIFOS.5 N,N-DIALLYLDICHLOROACETAMIDE exceptin preparations containing 10 per cent or less of

N,N-diallyldichloroacetamide.

7 4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).4 DIAMTHAZOLE.4 DIAVERIDINE.4 DIAZEPAM. (Appendix A, Appendix D)6 DIAZINON exceptwhen included in Schedule 5.

5 DIAZINON in dust preparations containing 2 per cent or less of diazinon.4 DIAZOXIDE.4 DIBENZEPIN.4 DIBOTERMIN.7 1,2-DIBROMO-3-CHLOROPROPANE.4 DIBROMOPROPAMIDINE for therapeutic use exceptwhen included in Schedule 2.2 DIBROMOPROPAMIDINE for ophthalmic use.6 DICAMBA (including its salts and derivatives) exceptwhen included in Schedule 5.5 DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of

dicamba.6 DICHLOBENIL.6 DICHLOFENTHION.6 DICHLOFLUANID.5 DICHLONE.4 DICHLORALPHENAZONE.6 ortho-DICHLOROBENZENE.5 para-DICHLOROBENZENE.6 DICHLOROETHYL ETHER.

6 DICHLOROISOCYANURIC ACID except:(a) when included in Schedule 5;(b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of

available chlorine when labelled with the statements:WARNING Ensure adequate ventilation when using. Vapour may be harmful. May give


31/100

TG147/97 Page 31of 100

off dangerous gas if mixed with other products;(c) in liquid preparations containing less than 2 per cent of available chlorine; or(d) in other preparations containing 4 per cent or less of available chlorine.

5 DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, exceptin:(a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of

available chlorine when labelled with the statements:WARNING Ensure adequate ventilation when using. Vapour may be harmful. May giveoff dangerous gas if mixed with other products;

(b) liquid preparations containing less than 2 per cent of available chlorine; or(c) other preparations containing 4 per cent or less of available chlorine.5 DICHLOROMETHANE (methylene chloride) except:

(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paintstrippers and containing 10 per cent or less of dichloromethane;

(b) in other preparations in pressurised spray packs; or(c) in paints and tinters containing 5 per cent or less of dichloromethane.

6 4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.6 DICHLOROPHEN except:

(a) when included in Schedule 4 or 5; or(b) in fabrics other than when:

(i) for human therapeutic use; or

(ii) as part of a registered pesticidal product.5 DICHLOROPHEN for the treatment of animals.4 DICHLOROPHEN for human therapeutic use.6 1,2-DICHLOROPROPANE.7 1,3-DICHLOROPROPENE.4 DICHLORPHENAMIDE.6 2,4-DICHLORPROP (including the R and S enantiomers).7 DICHLORVOS exceptwhen included in Schedule 5 or 6.6 DICHLORVOS in preparations containing 50 per cent or less of dichlorvos exceptwhen included

in Schedule 5.5 DICHLORVOS:

(a) when impregnated in plastic resin strip material containing 20 per cent or less dichlorvos;

(b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for thetreatment of animals; or

(c) in pressurised spray packs containing 10 grams or less of dichlorvos.DICHROMATES - see CHROMATES

5 DICLOBUTRAZOL.4 DICLOFENAC except:

(a) when included in Schedule 2 or 3; or(b) in preparations for dermal use unless:

(i) for the treatment of solar keratosis; or(ii) containing more than 4 per cent of diclofenac.

3 DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac perdosage unit in a pack containing 30 or less dosage units exceptwhen included in Schedule 2.

2 DICLOFENAC when:(a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage

unit in a pack containing 20 or less dosage units and labelled with a recommended dailydose of 75 mg or less of diclofenac; (b) in preparations for dermal use containing 4per cent or less of diclofenac except in preparations for dermal use containing 1 per cent

or less of diclofenac or for the treatment of solar keratosis; or(c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.

6 DICLOFOP-METHYL.5 DICLORAN.4 DICLOXACILLIN.5 DICOFOL.

7 DICOPHANE (DDT) for therapeutic use.7 DICROTOPHOS.6 DICYCLANIL exceptin preparations containing 5 per cent or less of dicyclanil.4 DICYCLOMINE.4 DIDANOSINE.


32/100

TG147/97 Page 32of 100

6 DIDECYLDIMETHYLAMMONIUM SALTS exceptin preparations containing 1 per cent or less ofdidecyldimethylammonium salts labelled with the statement:Avoid contact with eyes.

6 DIELDRIN.4 DIENESTROL.4 DIENOGEST.6 DIETHANOLAMINE (excluding its salts and derivatives) except:


(b) in preparations containing 5 per cent or less of diethanolamine.5 DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent orless of diethanolamine exceptin preparations containing 5 per cent or less of diethanolamine.

4 DIETHAZINE.4 DIETHYLCARBAMAZINE for human therapeutic use.7 DIETHYLENE GLYCOL for use in toothpastes or mouthwashes exceptin preparations

containing 0.25 per cent or less of diethylene glycol.6 DIETHYLENE GLYCOL (excluding its salts and derivatives) except:

(a) when included in Schedule 5;(b) in paints or paint tinters;(c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol;

or

(d) in other preparations containing 2.5 per cent or less of diethylene glycol.5 DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less

than 10mg/kg of denatonium benzoate as a bittering agent except:

(a) in paints or paint tinters;(b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol;

or(c) in other preparations containing 2.5 per cent or less of diethylene glycol.

5 DIETHYLENE GLYCOL MONOB

Date post:	02-Jun-2018
Category:	Documents
Upload:	muhammad-usman-nasir
View:	222 times
Download:	0 times

poisons-list-alpha.pdf

Documents